NEW YORK, Sept. 20 – Sequenom and Gemini Genomics have completed their stock-for-stock merger that has been in the works since May, the companies announced on Thursday. 

Sequenom, based in San Diego, nabbed Gemini Genomics for an as-yet undisclosed amount in stock in an attempt to boost its drug-development and clinical capabilities. The total dollar amount of the deal, originally said to be about $238 million, "is an open issue at the moment," a Sequenom spokesman said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.